And doc made a valid point when relooking at the guidance provided by Generex. “...and the company will initiate the clinical studies necessary to obtain that approval by Q4 2019.” If approval by that time it is reasonable to ask what’s the status of these studies. Or when looking at the 8k detailing a more aggressive development timeline than we’ve seen.